SInce 2010, FCF has awarded over $25.7 million in grants for research into fibrolamellar carcinoma. Following are details about each of the efforts that FCF has funded through its grant program.
Each grant award includes a brief summary of the project, its status (active or completed), the institution(s) that received the grant, the year of origination, the principal investigator, and the length of the grant commitment.
FCF’s most recent grant awards are listed first.
Each item in this list links to a dedicated page that contains the authoritative details for that item.
●
Dissecting and Harnessing SIK Tumor Suppressor Function in FLC Massachusetts General Hospital | 2025
View full details →
View full details →
●
●
Cellular and in vivo evaluation of DNAJ-PKAc modulator actionUniversity of California at San Francisco | 2025
View full details →
View full details →
●
Developing Precision Therapies for of Fibrolamellar Carcinoma (FLC)University of North Carolina | 2025
View full details →
View full details →
●
Investigating SLC16A14 in novel models of DNAJB1-PRKACA fusion driven cancerUniversity of Wisconsin | 2025
View full details →
View full details →
●
Biochemical and functional characterization of DNAJ-PKAc modulatorsUniversity of Washington | 2025
View full details →
View full details →
●
Fibrolamellar Carcinoma Cell Line Derivation and CharacterizationMassachusetts General Hospital | 2025
View full details →
View full details →
●
Development and implementation of 3D in vitro fibrolamellar carcinoma tumor modelsOhio State University | 2025
View full details →
View full details →
●
●
●
●
The Metabolic Implications and Targetability of Mitochondrial Calcium Signaling in FLCUniversity of Washington | 2025
View full details →
View full details →
●
Spatially resolving the tumor microenvironment of fibrolamellar carcinomaCornell University | 2025
View full details →
View full details →
●
FusionVAC22_02: DNAJB1-PRKACA fusion transcript-based peptide vaccine for fibrolamellar hepatocellular carcinoma patientsUniversity Hospital Tübingen | 2024
View full details →
View full details →
●
●
●
●
How fibrolamellar carcinoma differs from hepatocellular carcinoma in children – Creation of a multi-institutional database including central pathologic reviewCincinnati Children's Hospital Medical Center | 2023
View full details →
View full details →
●
Molecular therapies for fibrolamellar carcinoma (FLC) – continuationUniversity of Washington | 2023
View full details →
View full details →
●
Exploiting a Critical Vulnerability to Glutamine Antimetabolite Therapy in Fibrolamellar Hepatocellular Carcinoma (FLC)Johns Hopkins University and Dracen Pharmaceuticals | 2023
View full details →
View full details →
●
CRISPR-engineering of human liver organoids to study fibrolamellar carcinomaPrincess Maxima Center for Pediatric Oncology | 2023
View full details →
View full details →
●
Development of pre-clinical murine models for fibrolamellar hepatocellular carcinomaStanford University | 2023
View full details →
View full details →
●
Development and Characterization of Patient-derived Models of Fibrolamellar CarcinomaFred Hutchinson Cancer Center | 2023
View full details →
View full details →
●
Therapeutic modulation of tumor-infiltrating T cell function in fibrolamellar carcinomaUniversity of Washington | 2023
View full details →
View full details →
●
Selective translational inhibition as a treatment strategy for fibrolamellar liver cancerUniversity of California at San Francisco | 2023
View full details →
View full details →
●
●
Elucidation of nuclear-mitochondrial signaling by DNAJ-PKAc to define targeted vulnerabilities in FLCMassachusetts General Hospital | 2022
View full details →
View full details →
●
●
Novel synergistic combination therapy in fibrolamellar carcinomaUniversity of Wisconsin | 2022
View full details →
View full details →
●
●
Multicenter consortium to define the single-cell activity landscape of fibrolamellar carcinomaCornell University, Johns Hopkins University and St. Jude Children's Research Hospital | 2022
View full details →
View full details →
●
Defining the potential of DNAJB1-PRKACA fusion-specific T cells across human populationsSt. Jude Children's Research Hospital | 2022
View full details →
View full details →
●
Disruption of PKA RIα phase separation by the oncogenic fusion protein in FLCUniversity of California at San Diego | 2021
View full details →
View full details →
●
Defining incidence of fibrolamellar carcinoma through computational analysis of multiple data typesUniversity of California at San Francisco | 2021
View full details →
View full details →
●
Molecular therapies for fibrolamellar carcinoma (FLC) – extensionUniversity of Washington | 2021
View full details →
View full details →
●
CRISPR-engineering of human liver organoids to study fibrolamellar carcinomaPrincess Maxima Center for Pediatric Oncology | 2021
View full details →
View full details →
●
A gene editing approach to develop new and effective models for FLCUniversity of Wisconsin | 2021
View full details →
View full details →
●
●
Liquid Biopsy for Active Surveillance of Fibrolamellar Hepatocellular CarcinomaUniversity of Vermont | 2021
View full details →
View full details →
●
DNAJB1-PKAc-β-catenin-ALCD-dependent activation of cancer genes plays an essential role in fibrolamellar hepatocellular carcinomaCincinnati Children’s Hospital Medical Center | 2020
View full details →
View full details →
●
Identifying therapeutic vulnerabilities in fibrolamellar carcinomaCornell University | 2020
View full details →
View full details →
●
Cancer Research Institute (CRI) fellowship program – renewalCancer Research Institute | 2020
View full details →
View full details →
●
●
Creating a fibrolamellar cancer dependency mapBroad Institute of MIT and Harvard | 2020
View full details →
View full details →
●
Modulating stromal-immune cell interactions to activate anti-tumor immunity to fibrolamellar carcinomaUniversity of Washington | 2020
View full details →
View full details →
●
Fibrolamellar carcinoma model development and analysisMassachusetts General Hospital | 2020
View full details →
View full details →
●
Development of a human-derived liver progenitor cell line with DNAJB1-PRKACA fusion geneBoston Children’s Hospital | 2019
View full details →
View full details →
●
Expansion conditions for fibrolamellar carcinoma (FLC) organoidsUniversity of North Carolina | 2019
View full details →
View full details →
●
Retinoic acid-induced loss of DNAJB1-PRKACA fusion protein expressionCornell University | 2019
View full details →
View full details →
●
Targeting DNAJB1-PRKACA driven signaling dependencies in FLCUniversity of California at San Francisco, Massachusetts General Hospital | 2019
View full details →
View full details →
●
●
Molecular therapies for fibrolamellar carcinoma (FLC)University of Washington | 2019
View full details →
View full details →
●
●
●
Hedgehog and YAP signaling in fibrolamellar carcinoma: tumor-stroma crosstalk and the cancer stem cell nicheDuke University School of Medicine | 2017
View full details →
View full details →
●
●
Flipping the switch on PKA: synthetic lethal approaches to block PKA-driven tumor growth in fibrolamellar liver cancerUniversity of California at San Francisco, Massachusetts General Hospital | 2016
View full details →
View full details →
●
Developing therapeutics for fibrolamellar hepatocellular carcinomaRockefeller University | 2016
View full details →
View full details →
●
Pre-clinical studies of the interactions of the immune system with FL-HCCUniversity of California at San Francisco | 2016
View full details →
View full details →
●
●
●
●
●
●
Cancer Research Institute (CRI) fellowship programCancer Research Institute | 2016
View full details →
View full details →
●
Generation of T cells with specificity to FLC’s chimeric fusionJohns Hopkins University | 2015
View full details →
View full details →
●
Validating the RNA signature of fibrolamellar hepatocellular carcinomaUniversity of North Carolina | 2015
View full details →
View full details →
●
●
●
●
Creation of Fibrolamellar Tissue Repository at The Rockefeller UniversityRockefeller University | 2013
View full details →
View full details →
●
Genomic initiative on Fibrolamellar Hepatocellular CarcinomaRockefeller University | 2013
View full details →
View full details →
●
●
Analysis of the immunology, imaging and cell biology of fibrolamellar – continuedRockefeller University | 2011
View full details →
View full details →
●
●
Analysis of the immunology, imaging and cell biology of fibrolamellarRockefeller University | 2010
View full details →
View full details →
●
Establishment of FLC cell line and xenograft from FLC tumor samplesUniversity of British Columbia | 2010
View full details →
View full details →
●
Developmental biology of fibrolamellar hepatocellular carcinomaUniversity of North Carolina | 2010
View full details →
View full details →
●
●
